Sunesis Pharmaceuticals financials

View Company
Get notified regarding key financial metrics and revenue changes at Sunesis PharmaceuticalsLearn more
Banner background

Summary - Funding Rounds

Founding Date

1987

Total Funding

$171.7 m

Investors

New Enterprise Associates, Mayfield Fund, Venrock, Warburg Pincus, Alta Partners, Bridge Bank, Skyline Ventures, Bay City Capital, Vision Capital Advisors, Merlin Nexus, OpusPoint Partners, Caxton Advantage Life Sciences Fund, Abingworth, Nextech Invest, Credit Suisse First Boston, Rothschild & Cie, New Medical Technologies
In total, Sunesis Pharmaceuticals had raised $171.7 m. Sunesis Pharmaceuticals is a subsidiary of Viracta Therapeutics

Sunesis Pharmaceuticals Income Statement

Annual

USDFY, 2011FY, 2012FY, 2013FY, 2014FY, 2015FY, 2016FY, 2017FY, 2018FY, 2019FY, 2020

Revenue

5.0m3.8m8.0m5.7m3.1m2.5m669.0k237.0k2.1m120.0k

R&D expense

22.6m29.2m28.9m27.7m23.7m22.9m21.5m14.6m15.4m12.3m

General and administrative expense

8.3m9.2m10.8m23.1m18.7m16.1m13.5m11.3m9.9m10.2m

Operating expense total

30.9m38.4m39.7m50.8m42.4m39.0m35.1m25.9m25.4m22.4m

EBIT

(25.9m)(34.6m)(31.8m)(45.0m)(39.3m)(36.5m)(34.4m)(25.7m)(23.3m)(22.3m)

EBIT margin, %

(517%)(922%)(399%)(786%)(1284%)(1438%)(5145%)(10848%)(1123%)(18586%)

Interest expense

109.0k1.9m

Pre tax profit

(34.6m)(43.0m)(36.7m)(38.0m)(35.5m)(26.6m)(23.3m)(21.6m)

Income tax expense

Net Income

(20.1m)(44.0m)(34.6m)(43.0m)(36.7m)(38.0m)(35.5m)(26.6m)(23.3m)(21.6m)

Quarterly

USDQ2, 2011Q3, 2011Q1, 2012Q2, 2012Q3, 2012Q1, 2013Q2, 2013Q3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020Q3, 2020

Revenue

1.0m1.5m265.0k2.0m2.0m2.0m2.0m2.0m854.0k854.0k854.0k683.0k640.0k610.0k610.0k669.0k237.0k120.0k

R&D expense

6.0m6.2m6.6m8.1m6.9m7.4m7.7m7.0m7.6m7.2m6.9m4.5m6.3m5.3m6.2m6.6m5.3m6.2m4.9m6.8m4.0m3.8m3.6m3.2m3.7m3.5m3.7m4.3m2.2m

General and administrative expense

2.0m2.2m2.2m2.2m2.3m2.4m2.9m2.8m3.4m6.4m7.2m5.1m5.2m4.0m4.3m4.0m3.9m3.9m3.7m3.2m3.4m2.8m2.7m2.4m2.5m2.5m2.2m2.1m2.3m

Operating expense total

7.9m8.4m8.8m10.3m9.2m9.8m10.6m9.8m11.0m13.6m14.2m9.6m11.5m9.3m10.5m10.6m9.1m10.1m8.6m9.9m7.3m6.6m6.3m5.7m6.2m6.0m5.9m6.3m4.5m

Depreciation and amortization

2.0k2.0k

EBIT

(7.9m)(7.4m)(8.8m)(8.8m)(8.9m)(7.8m)(8.6m)(7.8m)(9.0m)(11.6m)(13.3m)(8.8m)(10.6m)(8.6m)(9.9m)(10.0m)(8.5m)(9.4m)(8.6m)(9.9m)(7.1m)(6.6m)(6.3m)(5.7m)(6.2m)(6.0m)(5.8m)(6.3m)(4.5m)

EBIT margin, %

(737%)(584%)(3375%)(394%)(431%)(391%)(450%)(583%)(1559%)(1027%)(1244%)(1255%)(1541%)(1638%)(1398%)(1410%)(2992%)(4832%)

Interest expense

315.0k316.0k385.0k831.0k768.0k

Net Income

(8.2m)(5.0m)(13.9m)(8.6m)(17.4m)(11.6m)(8.2m)(7.6m)(14.6m)(11.8m)(15.3m)(9.1m)(8.9m)(7.0m)(10.1m)(10.4m)(9.0m)(9.8m)(8.8m)(10.2m)(7.3m)(6.8m)(6.5m)(5.9m)(6.2m)(5.9m)(5.8m)(6.4m)(4.6m)

Sunesis Pharmaceuticals Balance Sheet

Annual

USDFY, 2011FY, 2012FY, 2013FY, 2014FY, 2015FY, 2016FY, 2017FY, 2018FY, 2019FY, 2020

Cash

9.3m14.9m15.1m22.2m26.9m8.1m27.0m13.7m12.8m20.4m

Prepaid Expenses

1.6m1.7m1.2m1.2m558.0k643.0k1.2m1.5m1.7m1.7m

Current Assets

45.7m72.9m40.5m44.2m47.0m43.2m32.9m15.2m36.3m22.1m

PP&E

74.0k43.0k23.0k42.0k14.0k3.0k20.0k11.0k3.0k

Total Assets

45.9m73.0m40.5m44.2m47.0m43.2m34.3m15.3m37.2m23.2m

Accounts Payable

658.0k78.0k953.0k3.2m2.5m1.9m1.7m1.4m791.0k479.0k

Short-term debt

6.6m9.0m9.3m7.8m3.3m7.2m7.4m6.0m273.0k

Current Liabilities

8.4m31.7m34.0m27.9m19.0m10.9m12.7m11.3m9.4m3.3m

Long-term debt

9.5m17.7m9.0m11.1m1.1m273.0k

Total Debt

9.5m24.3m18.0m9.3m7.8m14.4m7.2m14.8m7.1m546.0k

Total Liabilities

11.3m9.7m3.3m

Common Stock

5.0k5.0k5.0k7.0k9.0k2.0k3.0k4.0k11.0k2.0k

Preferred Stock

16.5m18.8m21.0m21.0m11.8m5.5m

Additional Paid-in Capital

429.1m457.0m473.5m536.5m570.3m599.6m633.4m642.5m698.6m718.8m

Retained Earnings

(401.1m)(445.1m)(479.7m)(522.7m)(559.4m)(597.4m)(632.9m)(659.5m)(682.8m)(704.4m)

Total Equity

28.0m12.0m(6.2m)13.8m27.4m21.0m21.5m4.0m27.5m19.9m

Debt to Equity Ratio

0.3 x2 x-2.9 x0.7 x0.3 x0.7 x0.3 x3.7 x0.3 x0 x

Debt to Assets Ratio

0.2 x0.3 x0.4 x0.2 x0.2 x0.3 x0.2 x1 x0.2 x0 x

Financial Leverage

1.6 x6.1 x-6.6 x3.2 x1.7 x2.1 x1.6 x3.8 x1.4 x1.2 x

Quarterly

USDQ2, 2011Q3, 2011Q1, 2012Q2, 2012Q3, 2012Q1, 2013Q2, 2013Q3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020Q3, 2020

Cash

7.6m11.9m5.3m11.7m41.6m12.6m6.6m21.7m50.4m26.8m20.8m18.8m20.3m16.8m23.9m9.4m5.8m11.5m11.7m7.9m21.4m17.0m20.2m24.8m9.8m19.7m20.0m17.7m26.0m

Prepaid Expenses

1.4m1.8m1.9m1.6m1.7m1.2m998.0k1.0m1.1m1.1m1.3m1.5m1.2m796.0k701.0k831.0k840.0k714.0k840.0k1.3m1.5m1.5m1.3m1.6m2.2m2.2m1.8m1.7m1.6m

Current Assets

50.3m43.5m36.7m30.9m78.2m62.2m50.6m46.5m71.8m59.7m46.0m41.3m40.7m31.3m40.7m34.0m25.1m35.9m23.5m13.7m26.9m21.9m21.5m26.4m19.8m40.5m30.7m24.9m27.6m

PP&E

94.0k82.0k66.0k58.0k50.0k36.0k31.0k27.0k41.0k35.0k53.0k31.0k19.0k17.0k11.0k8.0k6.0k1.0k25.0k22.0k18.0k16.0k14.0k9.0k7.0k5.0k1.0k

Total Assets

50.4m43.7m36.9m31.0m78.4m62.3m50.6m46.6m71.8m59.7m46.1m41.3m40.7m31.3m40.7m34.0m25.1m35.9m24.9m15.1m27.0m22.0m21.6m27.8m21.0m41.6m31.5m25.5m28.0m

Accounts Payable

329.0k327.0k869.0k393.0k1.2m1.5m2.1m1.5m1.0m513.0k772.0k2.1m2.3m1.8m2.6m2.8m2.5m2.6m2.3m1.5m1.0m1.6m1.3m861.0k692.0k770.0k862.0k452.0k150.0k

Short-term debt

50.0k900.0k4.4m8.2m8.5m8.8m9.3m9.6m9.9m713.0k3.3m5.9m833.0k2.1m4.6m1.7m2.5m7.3m7.3m7.3m6.6m6.0m6.0m6.0m6.0m409.0k

Current Liabilities

10.1m7.8m12.7m15.2m35.1m35.9m35.2m35.3m37.7m39.6m37.3m15.9m18.3m16.1m9.8m10.4m10.5m11.4m7.0m7.4m11.6m12.0m12.3m10.0m8.7m8.9m9.3m9.4m3.6m

Long-term debt

9.5m8.7m19.6m15.6m22.0m11.3m6.7m4.2m1.7m6.9m4.4m1.9m11.7m13.4m12.3m9.9m5.4m4.7m1.9m1.6m1.4m817.0k545.0k409.0k

Total Debt

9.5m9.6m24.0m23.8m30.5m20.0m16.0m13.8m11.6m7.6m7.7m7.8m11.7m14.3m14.4m14.5m7.1m7.2m14.5m14.6m14.7m12.1m10.9m10.9m6.8m6.6m818.0k

Total Liabilities

12.3m10.7m9.3m9.3m9.4m9.4m3.6m

Common Stock

5.0k5.0k5.0k5.0k5.0k5.0k5.0k5.0k6.0k6.0k6.0k7.0k7.0k8.0k9.0k9.0k1.0k2.0k2.0k2.0k3.0k4.0k4.0k7.0k7.0k11.0k11.0k11.0k2.0k

Preferred Stock

16.5m16.5m16.5m18.8m18.8m16.5m21.0m21.0m21.0m25.6m7.1m11.8m11.8m11.8m5.5m

Additional Paid-in Capital

427.7m428.2m429.7m430.7m451.0m457.8m459.1m466.7m520.0m521.9m525.0m548.6m558.0m559.8m572.3m573.5m574.6m602.8m609.7m612.6m634.5m636.0m641.8m656.8m676.2m698.0m698.9m699.3m718.5m

Retained Earnings

(387.4m)(392.4m)(415.1m)(423.6m)(441.0m)(456.7m)(464.9m)(472.5m)(494.3m)(506.0m)(521.4m)(531.8m)(540.8m)(547.8m)(569.5m)(579.9m)(588.9m)(607.2m)(616.1m)(626.2m)(640.1m)(647.0m)(653.5m)(665.3m)(671.6m)(677.5m)(688.6m)(695.0m)(699.6m)

Total Equity

40.3m35.8m14.7m7.1m10.0m1.1m(5.8m)(5.8m)25.8m15.8m3.6m16.8m17.2m12.1m19.3m10.1m2.2m14.3m12.5m2.9m15.4m10.0m9.3m17.1m11.7m32.3m22.1m16.1m24.5m

Debt to Equity Ratio

0.7 x1.4 x2.4 x21.6 x-5.3 x-3.5 x0.6 x0.9 x3.2 x0.5 x0.4 x0.6 x0.6 x1.4 x6.5 x1 x0.6 x2.5 x0.9 x1.5 x1.6 x0.7 x0.9 x0.3 x0.3 x0.4 x

Debt to Assets Ratio

0.3 x0.3 x0.3 x0.4 x0.6 x0.4 x0.2 x0.2 x0.3 x0.2 x0.2 x0.2 x0.3 x0.4 x0.6 x0.4 x0.3 x0.5 x0.5 x0.7 x0.7 x0.4 x0.5 x0.3 x0.2 x0.3 x

Financial Leverage

1.3 x1.2 x2.5 x4.4 x7.9 x56.4 x-8.8 x-8.1 x2.8 x3.8 x12.7 x2.5 x2.4 x2.6 x2.1 x3.4 x11.4 x2.5 x2 x5.2 x1.8 x2.2 x2.3 x1.6 x1.8 x1.3 x1.4 x1.6 x1.1 x

Sunesis Pharmaceuticals Cash Flow

Annual

USDFY, 2011FY, 2012FY, 2013FY, 2014FY, 2015FY, 2016FY, 2017FY, 2018FY, 2019FY, 2020

Net Income

(20.1m)(44.0m)(34.6m)(43.0m)(36.7m)(38.0m)(35.5m)(26.6m)(23.3m)(21.6m)

Depreciation and Amortization

56.0k31.0k20.0k29.0k27.0k11.0k9.0k9.0k(70.0k)(41.0k)

Accounts Payable

242.0k(580.0k)875.0k2.2m(724.0k)(582.0k)(174.0k)(304.0k)(602.0k)(312.0k)

Cash From Operating Activities

(22.8m)(10.6m)(37.4m)(43.2m)(38.7m)(37.0m)(36.1m)(24.4m)(22.2m)(21.4m)

Purchases of PP&E

(15.0k)(48.0k)(26.0k)

Cash From Investing Activities

4.2m(21.4m)32.2m3.3m1.2m(15.0m)29.7m4.8m(16.3m)16.4m

Short-term Borrowings

(7.2m)(9.4m)(1.6m)(8.0m)(7.6m)(7.5m)(5.5m)

Cash From Financing Activities

13.7m37.6m5.4m46.9m42.2m33.1m25.3m6.3m43.0m7.2m

Net Change in Cash

(4.9m)5.6m181.0k7.1m4.7m(18.8m)18.9m(13.3m)4.6m2.1m

Interest Paid

109.0k1.2m2.0m1.2m631.0k1.2m1.1m790.0k695.0k339.0k

Quarterly

USDQ2, 2011Q3, 2011Q1, 2012Q2, 2012Q3, 2012Q1, 2013Q2, 2013Q3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020Q3, 2020

Net Income

(6.4m)(11.4m)(13.9m)(22.5m)(39.9m)(11.6m)(19.8m)(27.4m)(14.6m)(26.4m)(41.7m)(9.1m)(18.1m)(25.1m)(10.1m)(20.5m)(29.5m)(9.8m)(18.7m)(28.8m)(7.3m)(14.1m)(20.6m)(5.9m)(12.1m)(18.0m)(5.8m)(12.2m)(16.8m)

Depreciation and Amortization

38.0k47.0k8.0k16.0k24.0k7.0k12.0k16.0k5.0k11.0k18.0k11.0k22.0k24.0k3.0k6.0k8.0k2.0k4.0k7.0k2.0k4.0k6.0k2.0k4.0k6.0k(37.0k)(41.0k)(41.0k)

Accounts Receivable

Accounts Payable

(87.0k)(89.0k)211.0k(265.0k)529.0k1.4m2.0m1.4m58.0k(440.0k)(181.0k)(1.1m)(895.0k)(1.4m)128.0k306.0k73.0k776.0k406.0k(330.0k)(659.0k)(144.0k)(420.0k)(532.0k)(701.0k)(623.0k)71.0k(339.0k)(641.0k)

Cash From Operating Activities

(8.9m)(15.6m)(9.3m)(15.1m)(1.4m)(9.5m)(19.0m)(27.7m)(11.4m)(21.6m)(34.2m)(11.6m)(19.8m)(29.5m)(10.7m)(20.1m)(29.0m)(9.7m)(20.5m)(30.8m)(6.5m)(12.4m)(17.9m)(6.1m)(13.0m)(18.4m)(5.7m)(11.5m)(15.8m)

Purchases of PP&E

(16.0k)(15.0k)(23.0k)(23.0k)(48.0k)(26.0k)(26.0k)

Cash From Investing Activities

(1.8m)9.2m5.2m17.1m(181.0k)7.8m13.3m32.7m3.9m(7.6m)206.0k(212.0k)1.5m7.1m3.4m(4.1m)1.1m10.8m23.5m30.0m742.0k1.4m4.8m(2.4m)(13.1m)13.0m16.4m16.4m

Short-term Borrowings

(694.0k)(2.8m)(5.0m)(2.3m)(4.6m)(6.9m)(1.6m)(1.6m)(1.6m)(830.0k)(830.0k)(830.0k)(7.5m)(7.6m)(1.4m)(7.5m)(7.5m)(5.5m)

Cash From Financing Activities

4.1m4.1m32.0k461.0k33.9m(653.0k)(2.6m)1.8m42.8m40.9m39.6m8.4m16.4m17.0m4.3m6.8m6.8m2.2m574.0k656.0k196.0k1.1m6.3m17.2m17.0m43.1m23.0k7.2m

Net Change in Cash

(6.6m)(2.3m)(4.0m)2.4m32.3m(2.4m)(8.3m)6.8m35.2m11.6m5.7m(3.4m)(1.9m)(5.4m)(3.0m)(17.4m)(21.1m)3.4m3.6m(109.0k)(5.6m)(9.9m)(6.8m)11.1m1.6m11.5m7.2m4.9m7.8m

Sunesis Pharmaceuticals Ratios

USDQ2, 2011

Financial Leverage

1.3 x

Sunesis Pharmaceuticals Employee Rating

4.26 votes
Culture & Values
5
Work/Life Balance
4.5
Senior Management
4.4
Salary & Benefits
3.5
Career Opportunities
3.4
Source
View Sunesis Pharmaceuticals profile

Need Data?

Craft can deliver 250+ data points of financial, operating, and human capital indicators on companies via API.

Learn more